LENZ Therapeutics, Inc.(US:LENZ)2025-05-27 13:45LNZ100 Product & Clinical Trial Highlights - LNZ100, an aceclidine eye drop, aims to provide seamless vision for the majority of 128 million US presbyopes, with a potential launch in Q4 2025[3],[5],[48] - Clinical trials showed 71% of participants achieved ≥3-line improvement at 0.5 hours and 40% at 10 hours[3] - 84% of participants achieved a 4-line gain at some point during the efficacy studies, and 52% achieved a 5-line gain[36] - 41% of participants achieved at least 1 line of distance vision improvement[44] Market Opportunity & Commercial Readiness - The presbyopia market is estimated to be a $3B+ market[3],[5],[59] - Phase 3 patient surveys indicated 75% interest for continued use of LNZ100[3],[49] - ECPs survey indicated that 61% (~215) of their ~350 monthly patients are presbyopic[51],[52] - At a conservative 6% adoption rate or ~8 million users and a 42% refill rate, LNZ100 has blockbuster potential[59] Financial Position & Exclusivity - The company ended Q1 2025 with $194.1M in cash and anticipates >$190M at PDUFA, with cash to positive cash flow[3] - The product has market exclusivity based on a broad IP portfolio and potential new chemical entity (NCE) status[3] - The company has 8 granted patents (Exp 2034-2044) and 7 patents under review (Exp 2034-2044) in the US[64]